☆ 4.6 Review

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review

ANTIBIOTICS-BASEL (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

Pranita D. Tamma et al.

Summary: The Infectious Diseases Society of America (IDSA) has provided updated guidance on the treatment of antimicrobial-resistant infections, focusing on treating AmpC-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. The guidance is based on clinical experience, expert opinion, and a review of available literature, as published data on optimal treatment options are limited. This document emphasizes treatment approaches for infections in the United States, considering differences in resistance epidemiology and the availability of specific anti-infectives internationally.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece

Dimitra Petropoulou et al.

Summary: This study evaluated the in vitro activity of the sulbactam-durlobactam (SD) combination against carbapenem-resistant A. baumannii isolates. SD demonstrated the lowest minimum inhibitory concentration (MIC90) and showed potential utility for the treatment of infections caused by A. baumannii. The addition of imipenem further enhanced the activity of SD.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)

Add to Collection

Article Infectious Diseases

In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance

Jacqueline Findlay et al.

Summary: This study investigated the resistance mechanisms of carbapenemase-producing Acinetobacter baumannii and evaluated the in vitro antibacterial activity of sulbactam combined with durlobactam. The results showed that sulbactam-durlobactam had excellent activity against A. baumannii isolates and identified potential mechanisms involved in resistance, including PBP substitutions and specific beta-lactamase production.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2022)

Add to Collection

Review Chemistry, Medicinal

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians

Luigi Principe et al.

Summary: Bacterial resistance mechanisms are continuously and rapidly evolving, especially for Gram-negative bacteria. The strategy of developing new beta-lactam/beta-lactamase inhibitors (BLs/BLIs) combinations has been successful, and data on several compounds are becoming available. Cefiderocol, with its unique mechanism of action, warrants separate discussion.

PHARMACEUTICALS (2022)

Add to Collection

Review Microbiology

Carbapenem-resistant Acinetobacter baumannii: A challenge in the intensive care unit

Yuan Jiang et al.

Summary: Carbapenem-resistant Acinetobacter baumannii (CRAB) has become a leading cause of healthcare-associated infections globally, particularly in intensive care units (ICUs). Cross-transmission between patients and the hospital environment may play a crucial role in ICU-acquired CRAB colonization and infection. The control and treatment of CRAB infection in ICUs are challenging due to its multiple-drug resistance. Therefore, it is important to systematically study the colonization, infection, transmission, and resistance mechanisms of CRAB in ICUs.

FRONTIERS IN MICROBIOLOGY (2022)

Add to Collection

Article Microbiology

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021

James A. Karlowsky et al.

Summary: Sulbactam-durlobactam demonstrated potent antibacterial activity against geographically diverse clinical isolates of Acinetobacter baumannii-calcoaceticus complex (ABC), including carbapenem-non-susceptible and multidrug-resistant (MDR) isolates.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy

Bernardetta Segatore et al.

Summary: The in vitro activity of the sulbactam-durlobactam (SUL-DUR) combination was evaluated against carbapenem-resistant A. baumannii (CRAb) clinical strains collected from multiple regions in Italy. The combination showed effectiveness against most isolates, with only a few exhibiting resistance due to the presence of additional resistance genes and mutations. The isolates also showed the presence of multidrug efflux pump genes associated with multidrug resistance.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-ResistantAcinetobacter baumannii: A Prospective, Observational Study

Alessandro Russo et al.

Summary: Severe pneumonia caused by multidrug-resistant Acinetobacter baumannii remains difficult to treat, and the choice of antibiotic regimen is debated due to poor lung penetration of most antibiotics. A study conducted from 2017 to 2020 found that septic shock and secondary bacteremia were associated with death, while a regimen containing fosfomycin was associated with improved 30-day survival. Different antibiotic regimens, with fosfomycin playing a predominant role, were used in treating the severe pneumonia caused by MDR-AB.

INFECTIOUS DISEASES AND THERAPY (2021)

Add to Collection

Review Microbiology

Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) Acinetobacter baumannii

Sunil Kumar et al.

Summary: Acinetobacter baumannii is a deadly opportunist pathogen in hospital-acquired infections, with limited treatment options due to the emergence of multidrug-resistant strains. Understanding the virulence factors of A. baumannii is crucial for overcoming this threat.

MICROORGANISMS (2021)

Add to Collection

Letter Infectious Diseases

In vitro activity of sulbactam/durlobactam against extensively drug-resistant Acinetobacter baumannii isolates belonging to South American major clones

Carolina S. Nodari et al.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)

Add to Collection

Review Microbiology

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Adam B. Shapiro et al.

Summary: The combination of durlobactam and sulbactam effectively inhibits multidrug-resistant Acinetobacter strains, enhancing the clinical utility of sulbactam.

FRONTIERS IN MICROBIOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017

Sarah M. McLeod et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Qiwen Yang et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Harald Seifert et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Review Microbiology

Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii

Corneliu Ovidiu Vrancianu et al.

MICROORGANISMS (2020)

Add to Collection

Article Microbiology

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

Melissa D. Barnes et al.

MBIO (2019)

Add to Collection

Article Immunology

Global Surveillance of the Activity of Sulbactam Combined With the Novel β-lactamase Inhibitor ETX2514 Against Clinical Isolates of Acinetobacter baumannii From 2014

Alita Miller et al.

Open Forum Infectious Diseases (2017)

Add to Collection

Article Microbiology

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

William F. Penwell et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

Add to Collection

Article Microbiology

Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii

Shu-Chen Kuo et al.

FRONTIERS IN MICROBIOLOGY (2015)

Add to Collection

Article Microbiology

Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections

Rujipas Sirijatuphat et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)

Add to Collection

Article Immunology

Update on Acinetobacter Species: Mechanisms of Antimicrobial Resistance and Contemporary In Vitro Activity of Minocycline and Other Treatment Options

Mariana Castanheira et al.

CLINICAL INFECTIOUS DISEASES (2014)

Add to Collection

Review Infectious Diseases

Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis

E. V. Lemos et al.

CLINICAL MICROBIOLOGY AND INFECTION (2014)

Add to Collection

Article Infectious Diseases

TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii

Lenka Krizova et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)

Add to Collection

Article Microbiology

Trends in Antimicrobial Resistance of Acinetobacter baumannii Isolates from a Metropolitan Detroit Health System

Tara Reddy et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.